JP2019150027A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019150027A5 JP2019150027A5 JP2019069638A JP2019069638A JP2019150027A5 JP 2019150027 A5 JP2019150027 A5 JP 2019150027A5 JP 2019069638 A JP2019069638 A JP 2019069638A JP 2019069638 A JP2019069638 A JP 2019069638A JP 2019150027 A5 JP2019150027 A5 JP 2019150027A5
- Authority
- JP
- Japan
- Prior art keywords
- klhl17
- biomarker
- breast cancer
- expression level
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001049220 Homo sapiens Kelch-like protein 17 Proteins 0.000 claims 66
- 102100023684 Kelch-like protein 17 Human genes 0.000 claims 66
- 239000000090 biomarker Substances 0.000 claims 50
- 238000000034 method Methods 0.000 claims 47
- 206010006187 Breast cancer Diseases 0.000 claims 35
- 208000026310 Breast neoplasm Diseases 0.000 claims 35
- UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 claims 24
- 229960003649 eribulin Drugs 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 17
- 239000000523 sample Substances 0.000 claims 9
- 210000001519 tissue Anatomy 0.000 claims 9
- 102000015694 estrogen receptors Human genes 0.000 claims 8
- 108010038795 estrogen receptors Proteins 0.000 claims 8
- 102000003998 progesterone receptors Human genes 0.000 claims 8
- 108090000468 progesterone receptors Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 102100028220 ABI gene family member 3 Human genes 0.000 claims 6
- 102100036438 Amyloid beta precursor protein binding family B member 2 Human genes 0.000 claims 6
- 102100022987 Angiogenin Human genes 0.000 claims 6
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims 6
- 108700020472 CDC20 Proteins 0.000 claims 6
- 101150023302 Cdc20 gene Proteins 0.000 claims 6
- 102100038099 Cell division cycle protein 20 homolog Human genes 0.000 claims 6
- 102100023309 Centrosomal protein of 152 kDa Human genes 0.000 claims 6
- 101710181192 Centrosomal protein of 152 kDa Proteins 0.000 claims 6
- 102000004360 Cofilin 1 Human genes 0.000 claims 6
- 108090000996 Cofilin 1 Proteins 0.000 claims 6
- 102100024335 Collagen alpha-1(VII) chain Human genes 0.000 claims 6
- 102100024901 Cytochrome P450 4F3 Human genes 0.000 claims 6
- 102100032881 DNA-binding protein SATB1 Human genes 0.000 claims 6
- 102100032248 Dysferlin Human genes 0.000 claims 6
- 102100032449 EGF-like repeat and discoidin I-like domain-containing protein 3 Human genes 0.000 claims 6
- 102100029988 Endoplasmic reticulum-Golgi intermediate compartment protein 3 Human genes 0.000 claims 6
- 102100038392 GRAM domain-containing protein 4 Human genes 0.000 claims 6
- 102100028260 Gamma-secretase subunit PEN-2 Human genes 0.000 claims 6
- 102100039261 Guanine nucleotide-binding protein G(t) subunit alpha-1 Human genes 0.000 claims 6
- 101000724234 Homo sapiens ABI gene family member 3 Proteins 0.000 claims 6
- 101000928680 Homo sapiens Amyloid beta precursor protein binding family B member 2 Proteins 0.000 claims 6
- 101000757236 Homo sapiens Angiogenin Proteins 0.000 claims 6
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 claims 6
- 101000888518 Homo sapiens Chemokine-like factor Proteins 0.000 claims 6
- 101000909498 Homo sapiens Collagen alpha-1(VII) chain Proteins 0.000 claims 6
- 101000909121 Homo sapiens Cytochrome P450 4F3 Proteins 0.000 claims 6
- 101000655234 Homo sapiens DNA-binding protein SATB1 Proteins 0.000 claims 6
- 101001016184 Homo sapiens Dysferlin Proteins 0.000 claims 6
- 101001016381 Homo sapiens EGF-like repeat and discoidin I-like domain-containing protein 3 Proteins 0.000 claims 6
- 101001010804 Homo sapiens Endoplasmic reticulum-Golgi intermediate compartment protein 3 Proteins 0.000 claims 6
- 101001033004 Homo sapiens GRAM domain-containing protein 4 Proteins 0.000 claims 6
- 101000579663 Homo sapiens Gamma-secretase subunit PEN-2 Proteins 0.000 claims 6
- 101000888178 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-1 Proteins 0.000 claims 6
- 101000962526 Homo sapiens Hyaluronidase-2 Proteins 0.000 claims 6
- 101001139130 Homo sapiens Krueppel-like factor 5 Proteins 0.000 claims 6
- 101000969581 Homo sapiens MOB kinase activator 1A Proteins 0.000 claims 6
- 101001091425 Homo sapiens Papilin Proteins 0.000 claims 6
- 101001062776 Homo sapiens Protein FAM234A Proteins 0.000 claims 6
- 101000601855 Homo sapiens Protocadherin-1 Proteins 0.000 claims 6
- 101001071164 Homo sapiens Pyridoxal phosphate phosphatase PHOSPHO2 Proteins 0.000 claims 6
- 101000633142 Homo sapiens Sorting nexin-11 Proteins 0.000 claims 6
- 101000881267 Homo sapiens Spectrin alpha chain, erythrocytic 1 Proteins 0.000 claims 6
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims 6
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 claims 6
- 101000648679 Homo sapiens Transmembrane protein 79 Proteins 0.000 claims 6
- 101000652472 Homo sapiens Tubulin beta-6 chain Proteins 0.000 claims 6
- 101000744742 Homo sapiens YTH domain-containing family protein 1 Proteins 0.000 claims 6
- 101000976649 Homo sapiens Zinc finger protein ZIC 5 Proteins 0.000 claims 6
- 102100039285 Hyaluronidase-2 Human genes 0.000 claims 6
- 108090000174 Interleukin-10 Proteins 0.000 claims 6
- 102000003814 Interleukin-10 Human genes 0.000 claims 6
- 102100020680 Krueppel-like factor 5 Human genes 0.000 claims 6
- 102100021437 MOB kinase activator 1A Human genes 0.000 claims 6
- 108010029782 Nuclear Cap-Binding Protein Complex Proteins 0.000 claims 6
- 102000001745 Nuclear Cap-Binding Protein Complex Human genes 0.000 claims 6
- 102100034934 Papilin Human genes 0.000 claims 6
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 claims 6
- 102100030560 Protein FAM234A Human genes 0.000 claims 6
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 claims 6
- 102100037551 Protocadherin-1 Human genes 0.000 claims 6
- 102100036843 Pyridoxal phosphate phosphatase PHOSPHO2 Human genes 0.000 claims 6
- 101100010298 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol2 gene Proteins 0.000 claims 6
- 102100029609 Sorting nexin-11 Human genes 0.000 claims 6
- 102100037608 Spectrin alpha chain, erythrocytic 1 Human genes 0.000 claims 6
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims 6
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 claims 6
- 102100028839 Transmembrane protein 79 Human genes 0.000 claims 6
- 102100030303 Tubulin beta-6 chain Human genes 0.000 claims 6
- 102100039647 YTH domain-containing family protein 1 Human genes 0.000 claims 6
- 102100023494 Zinc finger protein ZIC 5 Human genes 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 210000000481 breast Anatomy 0.000 claims 5
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 238000003018 immunoassay Methods 0.000 claims 5
- 239000003550 marker Substances 0.000 claims 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 238000004458 analytical method Methods 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 238000001574 biopsy Methods 0.000 claims 3
- 210000001124 body fluid Anatomy 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 claims 2
- 229960000439 eribulin mesylate Drugs 0.000 claims 2
- 125000003106 haloaryl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000006720 (C1-C6) alkyl (C6-C10) aryl group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 238000002875 fluorescence polarization Methods 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000005027 hydroxyaryl group Chemical group 0.000 claims 1
- 230000000951 immunodiffusion Effects 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000000019 nipple aspirate fluid Anatomy 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 238000012340 reverse transcriptase PCR Methods 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161454426P | 2011-03-18 | 2011-03-18 | |
| US61/454,426 | 2011-03-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017046070A Division JP6612280B2 (ja) | 2011-03-18 | 2017-03-10 | エリブリンに対する応答を予測するための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019150027A JP2019150027A (ja) | 2019-09-12 |
| JP2019150027A5 true JP2019150027A5 (enExample) | 2019-12-26 |
Family
ID=45879070
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558214A Pending JP2014509515A (ja) | 2011-03-18 | 2012-03-16 | エリブリンに対する応答を予測するための方法及び組成物 |
| JP2017046070A Expired - Fee Related JP6612280B2 (ja) | 2011-03-18 | 2017-03-10 | エリブリンに対する応答を予測するための方法及び組成物 |
| JP2019069638A Pending JP2019150027A (ja) | 2011-03-18 | 2019-04-01 | エリブリンに対する応答を予測するための方法及び組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558214A Pending JP2014509515A (ja) | 2011-03-18 | 2012-03-16 | エリブリンに対する応答を予測するための方法及び組成物 |
| JP2017046070A Expired - Fee Related JP6612280B2 (ja) | 2011-03-18 | 2017-03-10 | エリブリンに対する応答を予測するための方法及び組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9637795B2 (enExample) |
| EP (1) | EP2686441B1 (enExample) |
| JP (3) | JP2014509515A (enExample) |
| CN (1) | CN103562406B (enExample) |
| CA (1) | CA2828959A1 (enExample) |
| ES (1) | ES2731653T3 (enExample) |
| SG (2) | SG193489A1 (enExample) |
| WO (1) | WO2012129100A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA33127B1 (fr) | 2009-03-30 | 2012-03-01 | Eisai R&D Man Co Ltd | Composition liposomique |
| RU2689977C2 (ru) * | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
| JP6404242B2 (ja) * | 2013-06-26 | 2018-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 |
| EP3148526B1 (en) * | 2014-05-28 | 2021-01-06 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of cancer |
| WO2015184145A1 (en) * | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| EP3265122B1 (en) | 2015-03-04 | 2022-05-04 | Merck Sharp & Dohme Corp. | Combination of pembrolizumab and eribulin for treating triple-negative breast cancer |
| EP3290054B1 (en) | 2015-05-01 | 2022-04-13 | Japan Science and Technology Agency | Anti-tumor agent suppressing or inhibiting zic5 |
| PE20181953A1 (es) | 2016-03-02 | 2018-12-17 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso |
| US12029724B2 (en) | 2016-04-28 | 2024-07-09 | Eisai R&D Management Co., Ltd. | Method for inhibiting tumor growth |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2020179712A1 (en) * | 2019-03-01 | 2020-09-10 | Eisai R&D Management Co., Ltd. | Methods for predicting tumor response to eribulin |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CN113174427B (zh) * | 2021-04-29 | 2023-02-28 | 遵义医科大学 | 基于DNA分子检测ERGIC3 mRNA的方法 |
| CN113512733B (zh) * | 2021-05-13 | 2022-07-26 | 浙江工业大学 | 一种电化学nhk反应合成艾日布林中间体的方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| EP0916396B1 (en) | 1991-11-22 | 2005-04-13 | Affymetrix, Inc. (a Delaware Corporation) | Combinatorial strategies for polymer synthesis |
| ATE267877T1 (de) | 1993-01-07 | 2004-06-15 | Sequenom Inc | Dns - sequenzierung durch massenspektronomie |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| JP2001521753A (ja) | 1997-10-31 | 2001-11-13 | アフィメトリックス インコーポレイテッド | 成人臓器及び胎児臓器中の発現プロフィール |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| DK1087960T3 (da) | 1998-06-17 | 2011-06-14 | Eisai R&D Man Co Ltd | Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling |
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| WO2005032347A2 (en) | 2003-10-01 | 2005-04-14 | The Ohio State University Research Foundation | Determining the chemosensitivity of cells to cytotoxic agents |
| JP2008522623A (ja) * | 2004-12-09 | 2008-07-03 | エーザイ株式会社 | ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング |
| TW201132813A (en) * | 2010-03-03 | 2011-10-01 | Koo Foundation Sun Yat Sen Cancer Ct | Methods for classifying and treating breast cancers |
-
2012
- 2012-03-16 CA CA2828959A patent/CA2828959A1/en not_active Abandoned
- 2012-03-16 SG SG2013069646A patent/SG193489A1/en unknown
- 2012-03-16 US US14/001,737 patent/US9637795B2/en not_active Expired - Fee Related
- 2012-03-16 SG SG10201602147YA patent/SG10201602147YA/en unknown
- 2012-03-16 WO PCT/US2012/029479 patent/WO2012129100A1/en not_active Ceased
- 2012-03-16 ES ES12710643T patent/ES2731653T3/es active Active
- 2012-03-16 JP JP2013558214A patent/JP2014509515A/ja active Pending
- 2012-03-16 CN CN201280013701.8A patent/CN103562406B/zh not_active Expired - Fee Related
- 2012-03-16 EP EP12710643.3A patent/EP2686441B1/en active Active
-
2017
- 2017-03-10 JP JP2017046070A patent/JP6612280B2/ja not_active Expired - Fee Related
-
2019
- 2019-04-01 JP JP2019069638A patent/JP2019150027A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019150027A5 (enExample) | ||
| JP2014509515A5 (enExample) | ||
| JP2015517801A5 (enExample) | ||
| US20180080937A1 (en) | Biomarker Panel For Diagnosing Cancer | |
| JP6749337B2 (ja) | 前立腺抗原標準およびその使用 | |
| JP2012517241A5 (enExample) | ||
| KR20130002322A (ko) | 폐암 검출용 타액 바이오마커 | |
| JP2015503920A (ja) | 乳癌の予測および診断のためのバイオマーカー | |
| JP2012506253A (ja) | 大腸癌関連マーカーを用いた大腸癌の診断キット、及びそれを用いた大腸癌の診断方法 | |
| Lankiewicz et al. | Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment | |
| CN112567051A (zh) | 肝癌特异性生物标志物 | |
| JP2019527361A (ja) | 大腸癌の併用検査 | |
| JP2021517250A (ja) | 自己抗体−抗原結合体を利用した肺癌診断用免疫学的組成物、これを用いた肺癌診断方法及びこれを含む肺癌診断用キット | |
| JP2025518766A (ja) | 胃癌発病可能性の予測のためのバイオマーカー及びその用途 | |
| TWI598444B (zh) | 用以評估乳癌罹患風險之方法及基因標記 | |
| WO2020179712A1 (en) | Methods for predicting tumor response to eribulin | |
| KR101334123B1 (ko) | 소세포폐암 진단용 조성물 및 소세포폐암 진단키트 | |
| WO2016071321A2 (en) | Lung cancer sub-typing method | |
| KR102136747B1 (ko) | 장형 위암의 예후 진단 마커 | |
| JP2006525351A5 (enExample) | ||
| EP3701049B1 (en) | Diagnosis and/or prognosis of her2-dependent cancer using moesin as a biomarker | |
| EP1333278B1 (en) | Methods for monitoring and prognosis of disease course of gastrointestinal tumors | |
| Ayatollahi et al. | Chromogenic in situ hybridization compared with real time quantitative polymerase chain reaction to evaluate HER2/neu status in breast cancer | |
| EP1138780A1 (en) | Detection of disseminated tumor cells by quantitative RT-PCR of cytokeratin 20 mRNA | |
| US20250110132A1 (en) | Biomarkers for the determination of sample adequacy and lung cancer metastases |